糠酸莫米松对生活质量的影响：在伴持续性过敏性鼻炎的间歇性哮喘患者中采用鼻炎哮喘问卷调查的随机、安慰剂
2011/03/24
摘要
背景：过敏性鼻炎，特别是持续性过敏性鼻炎，且与哮喘相关时，可以严重影响患者的生活质量(QoL)。
目的：本试验采用鼻炎哮喘问卷调查评价糠酸莫米松喷鼻剂(MFNS)对伴持续性过敏性鼻炎的哮喘患者生活质量的影响。
方法：中重度持续性过敏性鼻炎和间歇性哮喘患者随机分为MFNS（无酒精，200 μg/d）组和安慰剂组，连续治疗28天。在治疗前、治疗后2周和4周，分别采用鼻炎哮喘问卷调查进行评价。每天记录总体5症状评分(T5SS)、哮喘症状评分和两个评分之和（症状总分[GSS]）。主要转归包括：治疗结束时的鼻炎哮喘总体汇总(GS)变化。次级终点是(a)从治疗开始至治疗结束间鼻炎哮喘因素的变化，这些因素包括：上气道(UAs)、下气道(LAs)、呼吸道过敏的影响；(b) 治疗开始至治疗结束间T5SS和GSS的变化；(c) 急救用药。
结果：52名成人患者进行随机分组。与安慰剂组相比，MFNS治疗组患者鼻炎哮喘的GS显著变化(-10.4 vs. 0.4; P<0.01)。同时，MFNS治疗能导致UA(-16.6 vs. 0.1; P<0.001)、LA (-10.8 vs. 1.1; P<0.001)和GSS (-6.7 vs. -3.1; P=0.019)的显著改善。虽然T5SS的变化在MFNS更为明显，但与安慰剂组相比，无统计学差异。
结论：伴持续鼻炎的间歇性哮喘患者，MFNS治疗能改善患者的生活质量和呼吸道症状负担。对鼻炎的治疗可能影响哮喘相关生活质量。
（刘国梁 审校）
Clin Exp Allergy. 2010 Dec 1. doi: 10.1111/j.1365-2222.2010.03660.x. [Epub ahead of print]
Effects of mometasone furoate on the quality of life: a randomized placebo-controlled trial in persistent allergic rhinitis and intermittent asthma using the Rhinasthma questionnaire.
Baiardini I, Villa E, Rogkakou A, Pellegrini S, Bacic M, Compalati E, Braido F, Le Grazie C, Canonica GW, Passalacqua G.
Allergy and Respiratory Diseases, Department of Internal Medicine, University of Genoa, Genoa, Italy Medical Division, Schering-Plough Spa, Milan, Italy.
Abstract
Background Allergic rhinitis, especially when persistent (PER) and associated with asthma heavily impairs patients’ quality of life (QoL). Objective This study assessed the effect of mometasone furoate nasal spray (MFNS) on the QoL of patients with PER and asthma, using the Rhinasthma questionnaire (EUDRACT n. 2007-004683-45). Methods Patients with moderate/severe PER and intermittent asthma were randomized to MFNS (alcohol-free) 200 μg/day or placebo for 28 days. Rhinasthma was completed at baseline and at weeks 2 and 4. The total five symptom score (T5SS) for rhinitis, the asthma symptom score and the sum of the two [global symptoms score (GSS)] were recorded daily. The primary outcome was the change in the Rhinasthma global summary (GS) at the end of treatment. Secondary end-points were (a) the change from baseline to end of treatment of each Rhinasthma factor: upper airways (UAs), lower airways (LAs) and respiratory allergy impact; (b) the change from baseline to end of treatment of the T5SS and of the GSS and (c) the use of rescue medication. Results Fifty-two adults were randomized. Compared with placebo, MFNS produced a significant change in the Rhinasthma GS (-10.4 vs. 0.4; P<0.01). MFNS also achieved a significant improvement of the UA (-16.6 vs. 0.1; P<0.001), LA (-10.8 vs. 1.1; P<0.001) and GSS (-6.7 vs. -3.1; P=0.019). The change of the T5SS was greater in the MFNS group but did not reach statistical significance. Conclusion In patients with PER rhinitis and intermittent asthma, MFNS improves the QoL and the burden of respiratory symptoms. Treating rhinitis may affect the asthma-related QoL
Clin Exp Allergy. 2010 Dec 1. doi: 10.1111/j.1365-2222.2010.03660.x. [Epub ahead of print]
背景：过敏性鼻炎，特别是持续性过敏性鼻炎，且与哮喘相关时，可以严重影响患者的生活质量(QoL)。
目的：本试验采用鼻炎哮喘问卷调查评价糠酸莫米松喷鼻剂(MFNS)对伴持续性过敏性鼻炎的哮喘患者生活质量的影响。
方法：中重度持续性过敏性鼻炎和间歇性哮喘患者随机分为MFNS（无酒精，200 μg/d）组和安慰剂组，连续治疗28天。在治疗前、治疗后2周和4周，分别采用鼻炎哮喘问卷调查进行评价。每天记录总体5症状评分(T5SS)、哮喘症状评分和两个评分之和（症状总分[GSS]）。主要转归包括：治疗结束时的鼻炎哮喘总体汇总(GS)变化。次级终点是(a)从治疗开始至治疗结束间鼻炎哮喘因素的变化，这些因素包括：上气道(UAs)、下气道(LAs)、呼吸道过敏的影响；(b) 治疗开始至治疗结束间T5SS和GSS的变化；(c) 急救用药。
结果：52名成人患者进行随机分组。与安慰剂组相比，MFNS治疗组患者鼻炎哮喘的GS显著变化(-10.4 vs. 0.4; P<0.01)。同时，MFNS治疗能导致UA(-16.6 vs. 0.1; P<0.001)、LA (-10.8 vs. 1.1; P<0.001)和GSS (-6.7 vs. -3.1; P=0.019)的显著改善。虽然T5SS的变化在MFNS更为明显，但与安慰剂组相比，无统计学差异。
结论：伴持续鼻炎的间歇性哮喘患者，MFNS治疗能改善患者的生活质量和呼吸道症状负担。对鼻炎的治疗可能影响哮喘相关生活质量。
（刘国梁 审校）
Clin Exp Allergy. 2010 Dec 1. doi: 10.1111/j.1365-2222.2010.03660.x. [Epub ahead of print]
Effects of mometasone furoate on the quality of life: a randomized placebo-controlled trial in persistent allergic rhinitis and intermittent asthma using the Rhinasthma questionnaire.
Baiardini I, Villa E, Rogkakou A, Pellegrini S, Bacic M, Compalati E, Braido F, Le Grazie C, Canonica GW, Passalacqua G.
Allergy and Respiratory Diseases, Department of Internal Medicine, University of Genoa, Genoa, Italy Medical Division, Schering-Plough Spa, Milan, Italy.
Abstract
Background Allergic rhinitis, especially when persistent (PER) and associated with asthma heavily impairs patients’ quality of life (QoL). Objective This study assessed the effect of mometasone furoate nasal spray (MFNS) on the QoL of patients with PER and asthma, using the Rhinasthma questionnaire (EUDRACT n. 2007-004683-45). Methods Patients with moderate/severe PER and intermittent asthma were randomized to MFNS (alcohol-free) 200 μg/day or placebo for 28 days. Rhinasthma was completed at baseline and at weeks 2 and 4. The total five symptom score (T5SS) for rhinitis, the asthma symptom score and the sum of the two [global symptoms score (GSS)] were recorded daily. The primary outcome was the change in the Rhinasthma global summary (GS) at the end of treatment. Secondary end-points were (a) the change from baseline to end of treatment of each Rhinasthma factor: upper airways (UAs), lower airways (LAs) and respiratory allergy impact; (b) the change from baseline to end of treatment of the T5SS and of the GSS and (c) the use of rescue medication. Results Fifty-two adults were randomized. Compared with placebo, MFNS produced a significant change in the Rhinasthma GS (-10.4 vs. 0.4; P<0.01). MFNS also achieved a significant improvement of the UA (-16.6 vs. 0.1; P<0.001), LA (-10.8 vs. 1.1; P<0.001) and GSS (-6.7 vs. -3.1; P=0.019). The change of the T5SS was greater in the MFNS group but did not reach statistical significance. Conclusion In patients with PER rhinitis and intermittent asthma, MFNS improves the QoL and the burden of respiratory symptoms. Treating rhinitis may affect the asthma-related QoL
Clin Exp Allergy. 2010 Dec 1. doi: 10.1111/j.1365-2222.2010.03660.x. [Epub ahead of print]
上一篇：
老年哮喘患者FoxP3、GATA-3和T-bet的表达
下一篇：
病毒诱导的急性哮喘患者中自然免疫信号受体特征
